Abstract
Background: Statistically significant positive correlations are reported for the abundance of hepatic drug-metabolising enzymes [1]. Current population-based physiologically-based pharmacokinetic (PBPK) models do not consider inter-correlations between the abundances of different enzymes when using Monte Carlo simulations to generate virtual individuals.
Aim: We investigate, as an example, the impact of CYP3A4-CYP2C8 inter-correlation on the predicted inter-individual variabilities of clearance and drug-drug interactions (DDIs) for repaglinide, a substrate of CYP2C8 and CYP3A4, using PBPK modelling.
Methods: PBPK modelling and simulation was employed using Simcyp Simulator (v15.1). Virtual populations were generated assuming inter-correlations between hepatic CYP3A4-CYP2C8 abundances derived from observed values in 24 human livers [1]. A repaglinide PBPK model was used to predict pharmacokinetic parameters in presence and absence of gemfibrozil, an inhibitor of CYP2C8, in virtual populations, and the results were compared with a clinical DDI study [2].
Results: Coefficient of variation (CV) of oral clearance was 52.5% in the absence of inter-correlation between CYP3A4-CYP2C8 abundances which increased to 54.2% when incorporating inter-correlation. In contrast, CV for predicted DDI (as measured by AUC ratio before and after inhibition) was reduced from 46.0% in the absence of inter-correlation between enzymes to 43.8% when incorporating inter-correlation: these CVs were associated with 5th/95th percentiles (2.48−11.29 vs. 2.49−9.69). The range of predicted DDI was larger in the absence of inter-correlation (1.55−77.06) than when incorporating inter-correlation (1.79−25.15), which was closer to clinical observations (2.6−12 [2]).
Conclusion: The present study demonstrates via a systematic investigation that population-based PBPK modelling incorporating inter-correlation led to more consistent estimation of extreme values with those observed in inter-individual variabilities of clearance and DDI. As the inter-correlations more realistically reflect enzyme abundances, virtual population studies involving PBPK and DDI should avoid using Monte Carlo assignment of enzyme abundance.
References:
[1] Achour B, et al. Drug Metab Dispos (2014), 42: 500-510.
[2] Tornio A, et al. Clin Pharmacol Ther (2008), 84: 403-411.
Aim: We investigate, as an example, the impact of CYP3A4-CYP2C8 inter-correlation on the predicted inter-individual variabilities of clearance and drug-drug interactions (DDIs) for repaglinide, a substrate of CYP2C8 and CYP3A4, using PBPK modelling.
Methods: PBPK modelling and simulation was employed using Simcyp Simulator (v15.1). Virtual populations were generated assuming inter-correlations between hepatic CYP3A4-CYP2C8 abundances derived from observed values in 24 human livers [1]. A repaglinide PBPK model was used to predict pharmacokinetic parameters in presence and absence of gemfibrozil, an inhibitor of CYP2C8, in virtual populations, and the results were compared with a clinical DDI study [2].
Results: Coefficient of variation (CV) of oral clearance was 52.5% in the absence of inter-correlation between CYP3A4-CYP2C8 abundances which increased to 54.2% when incorporating inter-correlation. In contrast, CV for predicted DDI (as measured by AUC ratio before and after inhibition) was reduced from 46.0% in the absence of inter-correlation between enzymes to 43.8% when incorporating inter-correlation: these CVs were associated with 5th/95th percentiles (2.48−11.29 vs. 2.49−9.69). The range of predicted DDI was larger in the absence of inter-correlation (1.55−77.06) than when incorporating inter-correlation (1.79−25.15), which was closer to clinical observations (2.6−12 [2]).
Conclusion: The present study demonstrates via a systematic investigation that population-based PBPK modelling incorporating inter-correlation led to more consistent estimation of extreme values with those observed in inter-individual variabilities of clearance and DDI. As the inter-correlations more realistically reflect enzyme abundances, virtual population studies involving PBPK and DDI should avoid using Monte Carlo assignment of enzyme abundance.
References:
[1] Achour B, et al. Drug Metab Dispos (2014), 42: 500-510.
[2] Tornio A, et al. Clin Pharmacol Ther (2008), 84: 403-411.
| Original language | English |
|---|---|
| Publication status | Published - 1 Jul 2018 |
| Event | The 18th World Congress of Basic and Clinical Pharmacology - Kyoto International Conference Center, Kyoto, Japan Duration: 1 Jul 2018 → 6 Jul 2018 http://www.wcp2018.org/information/outline.html |
Conference
| Conference | The 18th World Congress of Basic and Clinical Pharmacology |
|---|---|
| Abbreviated title | WCP2018 |
| Country/Territory | Japan |
| City | Kyoto |
| Period | 1/07/18 → 6/07/18 |
| Internet address |